We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| VistaGen Therapeutics Inc | NASDAQ:VTGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.12 | 2.67% | 4.62 | 4.55 | 4.65 | 4.6699 | 4.53 | 4.55 | 110,456 | 00:31:20 |
From May 2022 to May 2024
Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that Chief Executive Officer, Shawn Singh, will participate in the following upcoming investor conferences in New York. Management will be available for one-on-one meetings during these conferences.
Morgan Stanley 20th Annual Global Healthcare Conference
Format: Fireside Chat Date and Time: Tuesday, September 13th at 9:10 a.m. Eastern Time Location: New York, New York Webcast will be accessible through the Events page in the Investors section of the Company’s website at www.Vistagen.com.
Baird 2022 Global Healthcare Conference
Format: Fireside Chat Date and Time: Wednesday, September 14th at 2:35 p.m. Eastern Time Location: New York, New York
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. Vistagen’s clinical-stage candidates are targeting multiple forms of anxiety and depression. PH94B and PH10 belong to a new class of drugs known as pherines, which are odorless and tasteless investigational neuroactive steroids designed with a novel rapid-onset mechanism of action that activates chemosensory neurons in the nasal passages and can impact the olfactory-amygdala neural circuits without systemic uptake or direct activity on CNS neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression. Connect at www.Vistagen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220909005140/en/
Investors: Mark Flather Vice President, Investor Relations (650) 577-3617 mflather@vistagen.com
Media: Nate Hitchings SKDK nhitchings@skdknick.com
1 Year VistaGen Therapeutics Chart |
1 Month VistaGen Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
